FDA-Inspected Site

BMC 1092, Inc.

5 FDA inspections are on record for BMC 1092, Inc. in Broadview, United States.

Clean· No action indicated

Broadview, United States · Last updated July 10, 2026

Overview

  • 5 FDA inspections are on record.
  • 3 inspections produced a Form 483.
  • The most recent recorded inspection date is 2024-05-15.

At a glance

Inspections

5

Form 483s

3

EIRs

1

Last outcome

Clean

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
13 May 2024 – 15 May 2024Human DrugsClean
26 Oct 2021 – 10 Nov 2021Human Drugs483View 483 →
14 Sep 2016 – 28 Sep 2016Human Drugs483View 483 →
18 Feb 2014 – 13 Mar 2014Human Drugs483On file
9 Jan 2006Not recordedClean

Observations on record

Form 483 observations cited at this site, most recent first.

10 Nov 2021
21 CFR 211.113(a)

Procedures for non-sterile drug products

Cited by Brian D Nicholson, Vaishali J Patel

10 Nov 2021
21 CFR 211.192

Investigations of discrepancies, failures

Cited by Brian D Nicholson, Vaishali J Patel

28 Sep 2016
21 CFR 211.100(a)

Absence of Written Procedures

Cited by Brian D Nicholson

28 Sep 2016
21 CFR 211.166(a)(3)

Valid stability test methods

Cited by Brian D Nicholson

28 Sep 2016
21 CFR 211.113(a)

Procedures for non-sterile drug products

Cited by Brian D Nicholson

Investigators

FDA investigators tied to this site in the record.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.113(a)Cited across public-safe Form 483 observations2x
21 CFR 211.100(a)Cited across public-safe Form 483 observations1x
21 CFR 211.166(a)(3)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x

Full site report

Get the verbatim findings behind BMC 1092, Inc.'s 3 Form 483s

Source PDFs, verbatim observations, and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat